MarketPulse

schizophrenia

4 articles
BenzingaBenzinga··Globe Newswire

Reviva Pharma Raises $10M via Public Offering to Fund Schizophrenia Drug Trial

Reviva Pharma raises $10M via share offering priced at $1.50 per share to fund Phase 3 schizophrenia drug trial through March 2026 closing.
RVPHwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Reviva Pharma Raises $10M via Public Offering to Fund Schizophrenia Drug Trial

Reviva Pharmaceuticals prices $10M offering at $1.50/share to fund brilaroxazine Phase 3 schizophrenia trial and operations.
RVPHwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Minerva Neurosciences to Present CNS Pipeline at Stifel Forum Ahead of Key Phase 3 Trial

Minerva Neurosciences CEO to present at Stifel CNS Forum March 18, 2026, as company initiates Phase 3 roluperidone trial for schizophrenia treatment.
NERVbiopharmaceuticalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Minerva Neurosciences, Inc.

Minerva Neurosciences Posts $293M Loss But Bolsters Cash Reserves for Schizophrenia Drug Trial

Minerva Neurosciences reported $293.4M FY2025 net loss, largely from non-cash charges. The biotech secured $80M funding and plans Phase 3 roluperidone trial launch in Q2 2026.
NERVprivate placementPhase 3 trial